Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Premium
Indulgence
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21
Analysts estimate 38 per cent annual growth in earnings during FY20-22
Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD
In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022
Biocon's Q4 revenue hit by Covid-19 crisis, pre-tax profit declines 28%
The net profit for the period declined 42.2 per cent to Rs 123 crore on YoY basis, according to a BSE filing by the company
Biocon posts growth of 64% in net profit at Rs 213.7 cr during Q4
Strong performance owing to growth in biologics, research services and small molecules business, says company
